1st Line Chemotherapy Alone or With Bevacizumab in Treating Older Patients With Metastatic Colorectal Cancer
Status:
Completed
Trial end date:
2016-04-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy, such as leucovorin calcium, fluorouracil, irinotecan
hydrochloride, and oxaliplatin, work in different ways to stop the growth of tumor cells,
either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as
bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells
to grow and spread. Others find tumor cells and help kill them or carry tumor-killing
substances to them. Giving bevacizumab together with combination chemotherapy may be a better
way to block tumor growth. It is not yet known whether combination chemotherapy is more
effective when given together with or without bevacizumab in treating patients with
colorectal cancer.
PURPOSE: This randomized phase II trial is studying the side effects of giving bevacizumab
together with first-line chemotherapy and to see how well it works in treating older patients
with metastatic colorectal cancer.